The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis

Journal of Heart Valve Disease

Volumn 20, Issue 1, 2011, Pages 18-22

  Dimitrow, Pawel Petkow ^a   Jawień, Marek ^b   Gackowski, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Outpatient Cardiologic Clinic   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; SPP1 PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

AGED; AORTA ATHEROSCLEROSIS; AORTA STENOSIS; ARTERY CALCIFICATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AORTA VALVE STENOSIS; BLOOD; CALCINOSIS; CLINICAL TRIAL; DOPPLER ECHOCARDIOGRAPHY; DOWN REGULATION; DRUG ADMINISTRATION; ECHOGRAPHY; HOSPITALIZATION; MIDDLE AGED; POLAND; SCLEROSIS; TIME; TREATMENT OUTCOME;

AGED; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; CALCINOSIS; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OSTEOPONTIN; OSTEOPROTEGERIN; POLAND; PYRROLES; RANK LIGAND; SCLEROSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953829025     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-147
2. Nightingale AK, Horowitz JD. Aortic sclerosis: Not an innocent murmur but a marker of increased cardiovascular risk. Heart 2005;91:1389-1393
3. Antonini-Canterin F, Hirsu M, Popescu BA, et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008;102:738-742
4. Shah SJ, Ristow B, Ali S, Na BY, Schiller NB, Whooley MA. Acute myocardial infarction in patients with versus without aortic valve sclerosis and effect of statin therapy (from the Heart and Soul Study). Am J Cardiol 2007;99:1128-1133
5. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-2397
6. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356
7. Chan KL, Teo K, Dumesnil JG, et al.; for the ASTRONOMER Investigators. Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis. Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial. Circulation 2010;121:306-314
8. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-561
9. Akat K, Borggrefe M, Kaden JJ. Aortic valve calcification - basic science to clinical practice. Heart 2009;95;616-623
10. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-2180
11. Yu PJ, Skolnick A, Ferrari G, et al. Correlation between plasma osteopontin levels and aortic valve calcification: Potential insights into the pathogenesis of aortic valve calcification and stenosis. J Thorac Cardiovasc Surg 2009;138:196-199
12. Steinmetz M, Skowasch D, Wernert N, et al. Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves. J Heart Valve Dis 2008;17:187-193
13. Losi MA, Brevetti G, Schiano V, et al. Aortic valve sclerosis in patients with peripheral and/or coronary arterial disease. Echocardiography 2010;27:608-612
14. .Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204:321-329
15. Atalar E, Ozturk E, Ozer N, et al. Plasma soluble osteopontin concentrations are increased in patients with rheumatic mitral stenosis and associated with the severity of mitral valve calcium. Am J Cardiol 2006;98:817-820
16. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-1194
17. Minoretti P, Falcone C, Calcagnino M, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802-807
18. Tanaka N, Momiyama Y, Ohmori R, et al. Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006;26:e129-e130
19. Kadoglou NP, Gerasimidis T, Moumtzouoglou A, et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg 2008;35:661-668
20. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Gerasimidis T, Liapis CD. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J Vasc Surg 2010;51:114-121
21. Helske S, Otto CM. Lipid lowering in aortic stenosis: Still some light at the end of the tunnel? Circulation 2009;119:2653-2655
22. Miller JD, Weiss RM, Serrano KM, et al. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 2009;119:2693-2701
23. Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002;105:2660-2665
24. Rajamannan NM. Calcific aortic stenosis: Lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 2009;29:162-168
25. .Völzke H, Haring R, Lorbeer R, et al. Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis 2010;209:606-610
26. Skowasch D, Tuleta I, Steinmetz M, et al. Pathogen burden in degenerative aortic valves is associated with inflammatory and immune reactions. J Heart Valve Dis 2009;18:411-417
27. Nagila A, Permpongpaiboon T, Tantrarongroj S, et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 2009;61:892-898
28. Jassal DS, Bhagirath KM, Tam JW, et al. Association of bicuspid aortic valve morphology and aortic root dimensions: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. Echocardiography 2010;27:174-179